GRUPO CASA SABA SA DE CV Form 6-K May 01, 2009

Quarterly Earnings Report

April 30, 2009

1Q09

Sales and Operating Income Increased 7.10% and 4.27%, Respectively

Financial Highlights:

(All figures are expressed in millions of Mexican pesos of purchasing power as of March 2009. Comparisons are made with the same period of 2008, unless otherwise stated. Figures may vary due to rounding practices. "bp" stands for basis points)

♦ Sales for the quarter totaled \$7,426.30 million, an increase of 7.10%
 ♦ Gross income rose 26.84% to reach \$829.64 million
 ♦ The gross margin for the quarter was 11.17%, 174 bp higher than in 1Q08
 ♦ Quarterly operating expenses as a percentage of sales were 7.52%
 ♦ Operating income grew 4.27% versus 1Q08
 ♦ The operating margin for the quarter was 3.65%
 ♦ Operating income plus depreciation and amortization for the period was \$290.34 million, an increase of 4.86% versus 1Q08
 ♦ Net profit for the quarter was \$179.94 million
 ♦ Cash and cash equivalents at the end of the quarter was \$120.76 million

Mexico City, Mexico, April 30, 2009. Grupo Casa Saba ("Saba", "GCS", "the Company" or "the Group"), one of the leading Mexican distributors of pharmaceutical products, beauty aids, personal care and consumer goods, general merchandise, publications and other products announces its consolidated financial and operating results for the first quarter of 2009.

QUARTERLY EARNINGS

NET SALES

During the first quarter of 2009, GCS's sales were \$7,426.30 million, an increase of 7.10%.

SALES BY DIVISION

PRIVATE PHARMA

Sales in our Private Pharma division rose 8.51% during the first quarter of 2009, as a result of the consolidation of investments that were made within the sector. This includes the acquisition of *Drogasmil Medicamento e Perfumeria, S.A.*, a Brazilian pharmacy chain, in May 2008.

Sales for this division reached \$6,640.45 million and represented 86.99% of the Group's total sales.

GOVERNMENT PHARMA

Sales in our Government Pharma division decreased 10.54% due to changes in the bidding processes of Petróleos Mexicanos (PEMEX) and the Secretary of Health (SSA by its Spanish acronym), which resulted in a reduction in consumption during the period.

As a percentage of total sales, this division went from representing 2.70% in 1Q08 to 2.26% during the first quarter of 2009.

HEALTH, BEAUTY, CONSUMER GOODS, GENERAL MERCHANDISE AND OTHER

Sales in our Health, Beauty, Consumer Goods, General Merchandise and Other division reached \$618.23 million, an increase of 2.31% versus the first quarter of 2008. This was due to commercial agreements that enabled us to increase promotions and discounts which, in turn, increased our sales.

This division represented 8.33% of GCS's total sales in 1T09, a decrease of 38 b.p. compared to the same period of the previous year. This decrease was due to the significant increase in the participation of the Private Pharma division as a percentage of total sales.

PUBLICATIONS

Publication sales decreased 4.66% during the quarter, primarily as a result of lower unit sales. This decrease was mainly due to the fact that Citem stopped distributing some publications that no longer met our minimal profitability requirements.

This division's participation as a percentage of total sales went from 2.72% in 1Q08 to 2.42% in the first quarter of 2009.

The sales mix did not change significantly this quarter. Private Pharma sales represented 86.99% of total sales (compared to 85.86% during the first quarter of 2008), while Government Pharma accounted for 2.26% (versus 2.70% during the first quarter of 2008). Health, Beauty, Consumer Goods, General Merchandise and Other represented 8.33% (compared to 8.71% in the first quarter of 2008) and Publications made up the remaining 2.42% (versus 2.72% during the first quarter of 2008).

Division % of sales
Private Pharma 86.99%
Government Pharma 2.26%
Health, Beauty, Consumer Goods,
General Merchandise and Other Publications 2.42%

TOTAL 100.00%

GROSS INCOME

During the first quarter of the year, Grupo Casa Saba's gross income increased 26.84% to reach \$829.64 million. The company's gross margin improved as a result of the growth in sales derived from recent investments and a reduction in the Sales Costs as a percentage of total sales, from 9.43% in 1Q08 to 11.17% during the current period.

OPERATING EXPENSES

Operating expenses reached \$558.58 million, an increase of 41.72% compared to the first quarter of 2008. This was due to the investments that were made in the Private Pharma division. Operating expenses represented 7.52% of our total sales.

OPERATING INCOME

Operating income rose 4.27%, as a result of the increase in sales which offset the increase in operating expenses. The operating margin was 3.65%, 10 b.p. lower than the 3.75% margin registered in the first quarter of 2008.

OPERATING INCOME PLUS DEPRECIATION AND AMORTIZATION

Operating income plus depreciation and amortization for 1Q09 was \$290.34 million, an increase of 4.86% compared to the first quarter of 2008. Depreciation and amortization for the period was \$19.28 million, 13.98% higher than in the first quarter of 2008.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents at the end of the first quarter of 2009 was \$120.76 million.

COMPREHENSIVE COST OF FINANCING

During the period, GCS's comprehensive cost of financing (CCF) was \$62.59 million, due primarily due to an increase in the amount of interest income paid.

The interest payments were related to the long-term credit that was obtained as a result of the acquisition in Brazil as well as the interest that was generated from the utilization of short-term credits for our operations in both Mexico and Brazil.

OTHER EXPENSES (INCOME)

During the first quarter of 2009, the Company registered an income of \$25.09 million in other expenses (income). The expenses (income) from this line item were derived from activities that are distinct from the company's everyday business operations.

TAX PROVISIONS

During the first quarter, tax provisions were \$53.61 million and were entirely related to income taxes.

NET INCOME

GCS's net income for the first quarter was \$179.94 million, an decrease of 6.09% compared to the first quarter of 2008.

The net margin for the period was 2.42%, slightly lower than the 2.76% net margin registered during the first quarter of 2008.

WORKING CAPITAL

During the first quarter of 2009, our accounts receivable days were 62.6 days, a decline of 7.6 days compared to 1T08. In addition, our accounts payable days decreased by 1.0 days versus 1Q08, to reach 65.2 days. Finally, our inventory days were 52.6 days, a decline of 3.3 days.

The 265.4 million shares issued by Grupo Casa Saba are listed on the Mexican Stock Exchange and its ADRs on the New York Stock Exchange, both under the symbol "SAB". One ADR equals 10 ordinary shares.

Grupo Casa Saba is one of the leading distributors of pharmaceutical products, beauty, personal care and consumer goods, general merchandise, publications and other goods in Mexico. With 115 years of experience, the Company distributes to the majority of pharmacies, chains, self-service and convenience stores, as well as other specialized national chains.

As a precautionary note to investors, except for the historic information contained herein, certain topics discussed in this document constitute forward-looking statements. Such topics imply risks and uncertainties, including the economic conditions in Mexico and other countries in which Casa Saba operates, as well as variations in the value of the Mexican peso as compared with the US dollar.

Contacts:

GRUPO CASA SABA Sandra Yatsko +52 (55) 5284-6698 syatsko@casasaba.com IR Communications: Jesús Martínez Rojas +52 (55) 5644-1247 jesus@irandpr.com

Alejandro Sadurni, CFO asadurni@casasaba.com

GRUPO CASA SABA S.A.B. DE C.V. AND SUB	SSIDIARIES CONSOLIDATED BALANCE SHEET	Figures are
expressed in thousands of current Mexican pesos	ITEM March-09 March-08 Variation	TOTAL
ASSETS		

13,622,869 10,903,280 2,719,588

CURRENT ASSETS	
CURRENT ASSETS	10 660 172
	10,660,172
	9,305,532
CACH AND CACH FOUNTAL ENTO	1,354,639
CASH AND CASH EQUIVALENTS	400 707
	120,767
	178,037
	(57,269)
ACCOUNTS RECEIVABLE (NET)	
	5,793,961
	4,823,379
	970,582
INTERCOMPANY	
OTHER ACCOUNTS RECEIVABLE (NET)	
	525,339
	525,779
	(440)

OTHER CURRENT ASSETS

INVENTORIES

125,158 110,003 **15,155**

4,094,946 3,668,335 **426,611**

LONG TERM

ACCOUNTS RECEIVABLE INVESTMENTS IN EQUITY SHARES AND UNCONSOLIDATED SUBSIDIARIES OTHER INVESTMENTS

NET PROPERY, PLANT AND EQUIPMENT	
PROPERTY	1,367,311 1,210,963 156,348
	1,354,415 1,313,863 40,551
MACHINERY AND EQUIPMENT	505,990 461,154 44,83 6
OTHER EQUIPMENT	650,409 564,827 85,581
ACCUMULATED DEPRECIATION	1,143,502 1,128,881 14,621
BUILDINGS IN PROCESS DEFERRED ASSETS (NET)	1,305,125
OTHER ASSETS	218,231 1,086,895
	290,261 168,554 121,707
TOTAL LIABILITIES	7,068,168 4,483,885 2,584,283
CURRENT LIABILITIES	5,462,326 3,857,722 1,604,603
ACCOUNTS PAYABLE	4,090,648 3,678,085 412,563
	412,500
BANK DEBT	845,451
BANK DEBT DEBT SECURITIES ACCRUED TAXES OTHER CURRENT LIABILITIES	845,451 845,451 526,227

	179,638 346,589
LONG TERM LIABILITIES	1,118,000 1,118,000
BANK DEBT	1,118,000 1,118,000
DEBT SECURITIES OTHER DEBT DEFERRED LIABILITIES OTHER LIABILITIES	487,842 626,162 (138,320)
SHAREHOLDER'S EQUITY	6,554,701 6,419,396 135,305
MINORITY STOCKHOLDER'S EQUITY MAJORITY STOCKHOLDER'S EQUITY	
PAID-IN CAPITAL	6,554,701 6,419,396 135,305 1,992,326 1,992,325
CAPITAL STOCK	(0) 167,903 167,903
RESTATEMENT IN CAPITAL STOCK	955,862 955,862
PREMIUM ON STOCK SOLD	(0) 868,561 868,561
RESERVE FOR RESTATEMENT ON SHAREHOLDER'S EQUITY CAPITAL INCREASE (DECREASE)	(0)
CUMMULATIVE RESULTS AND EQUITY RESERVE	4,562,375 4,427,070 135,305 6,057,256 5,546,997
RESERVE FOR SHARES REPURCHASE	510,259 1,063,517 1,063,517 0

OVERAGE (DEFICIT) ON RESTATEMENT ON STOCKHOLDER'S EQUITY

(2,738,339) (2,375,060) **(363,279)**

NET INCOME

179,941 191,617 **(11,676)**

GRUPO CASA SABA, S.A.B. DE C.V. Figures are expressed in thousands of current

Mexican pesos. Jan-Mar Jan-Mar Variation Income Statement 2008 % of sales \$ 900 % of sales \$ 100 NET SALES

100.00% 7,426,300 100.00% 492,269

7.10%

6,934,031

COST OF SALES

6,279,940 90.57% 6,596,656 88.83% 316,716

5.04%

654,091

Gross Profit

9.43% 829,644 11.17% 175,553

26.84%

Operating Expenses
Sales Expenses

153,306 2.21% 220,166 2.96% 66,860

43.61%

Administrative Expenses

240,831 3.47% 338,423 4.56%

97,592 40.52%

OPERATING EXPENSES

394,137 5.68% 558,589 7.52% 164,452 41.72%

Operating Income

259,955 3.75%

271,055 3.65% 11,101 4.27% COMPREHENSIVE COST OF FINANCING Interest Paid 6,507 0.09% 61,622 0.83% 55,115 847.00% Interest (Earned) -535 (0.01%)-1,234 (0.02%)-699 130.68% Exchange Loss (Gain) -178 0.00% 2,205 0.03% 2,382 (1340.93%)Monetary Position (gain) 0 0.00% 0 (0.00%)0.00% Comprehensive Cost of Financing 5,795 0.08% 62,593 0.84% 56,798 980.19% OTHER EXPENSES (INCOME), net -2,494 (0.04%)-25,093 (0.34%)22,600 906.25% **NET INCOME BEFORE TAXES** 256,654 3.70% 233,556 3.14% -23,098 (9.00%)PROVISIONS FOR: Income Tax 100,700

Asset Tax Deferred Income Tax	0 0.00% 0 0.00% 0 0.00% -35,663 (0.51%)
Deformed Income Toy	0.00% 0 0.00% -35,663 (0.51%)
Deformed Income Toy	0.00% -35,663 (0.51%)
	(0.51%)
	0
	(0.00%) 35,663
Profit sharing due	00.00%)
	0.00%
	0.00% 0
Deferred Profit sharing due	0.00%
	0 0.00% 0
	0.00%
Total taxes	0.00%
	65,037 0.94%
	53,614 0.72% -11,422
(17.56%)
Net Income Before Extraordinary Items	191,617
	2.76% 179,941
	2.42% -11,676 (6.09%)
Extraordinary Items (Income)	(0.0070)
	0 0.00%
	0.00%
Net Income	0.00%
	191,617 2.76% 179,941 2.42% -11,676

	(6.09%)
Depreciation and Amortization	
	16,919
	0.24%
	19,284
	0.26%
	2,366
	13.98%
Operating income plus Depreciation and Amortization	
	276,873
	3.99%
	290,340
	3.91%
	13,466
	4.86%
Minority Interest	
,	

1,439 0.02% 1,439 0.00%